tetano
Editor, Senior Moderator
Oncologist
. 2021 May 24.
doi: 10.1002/onco.13831. Online ahead of print.
COVID-19 in cancer patients: A retrospective study of 212 cases from a French SARS-CoV-2 cluster during the first wave of the COVID-19 pandemic
Sophie Martin[SUP] 1 [/SUP], Charlotte Kaeuffer[SUP] 2 [/SUP], Pierre Leyendecker[SUP] 3 [/SUP], Nicolas Tuzin[SUP] 4 [/SUP], Youssef Tazi[SUP] 5 [/SUP], Frédérique Schaff-Wendling[SUP] 6 [/SUP], Tiffanie Kleinheny[SUP] 7 [/SUP], Stéphanie Husson-Wetzel[SUP] 8 [/SUP], Guillaume Pamart[SUP] 9 [/SUP], Jean-Marc Limacher[SUP] 10 [/SUP], Olivier Clerc[SUP] 11 [/SUP], Elise Dicop[SUP] 1 [/SUP], Jean-Emmanuel Kurtz[SUP] 1 [/SUP], Philippe Barthélémy[SUP] 1 [/SUP], Justine Gantzer[SUP] 1 [/SUP]
Affiliations
Abstract
We describe a large series of solid tumor patients in an early Coronavirus Disease 2019 (COVID-19) cluster of the eastern part of France. From February to May 2020, this multicenter retrospective study enrolled 212 cancer patients under treatment or on follow-up for any type of malignant solid tumor and positive for severe acute respiratory coronavirus 2. The mortality rate was 30%. Patients with gastrointestinal cancers were identified like a subset of more vulnerable cancer patients and immunotherapy or radiotherapy within 3 months from COVID-19 diagnosis were risk factors for death. The reported data support the essential need to be proactive and weigh the risks of morbidity from COVID-19 against the magnitude of benefits of intended cancer therapies during this pandemic. IMPLICATIONS FOR PRACTICE: This article supports the essential need to be proactive (treatment delay or modification) in oncology in the setting of pandemic. Indeed, we identified gastrointestinal cancers like a subset of more vulnerable cancer patients and found that immunotherapy and radiotherapy within 3 months from COVID-19 diagnosis as risk factors for death. The reported data indicate the necessity to weigh the risks of morbidity from COVID-19 against the magnitude of benefits of intended cancer therapies so that the situation would be different if there were another wave of COVID-19.
Keywords: COVID-19; Cancer; mortality; patients' management; retrospective cohort; risk factor.
. 2021 May 24.
doi: 10.1002/onco.13831. Online ahead of print.
COVID-19 in cancer patients: A retrospective study of 212 cases from a French SARS-CoV-2 cluster during the first wave of the COVID-19 pandemic
Sophie Martin[SUP] 1 [/SUP], Charlotte Kaeuffer[SUP] 2 [/SUP], Pierre Leyendecker[SUP] 3 [/SUP], Nicolas Tuzin[SUP] 4 [/SUP], Youssef Tazi[SUP] 5 [/SUP], Frédérique Schaff-Wendling[SUP] 6 [/SUP], Tiffanie Kleinheny[SUP] 7 [/SUP], Stéphanie Husson-Wetzel[SUP] 8 [/SUP], Guillaume Pamart[SUP] 9 [/SUP], Jean-Marc Limacher[SUP] 10 [/SUP], Olivier Clerc[SUP] 11 [/SUP], Elise Dicop[SUP] 1 [/SUP], Jean-Emmanuel Kurtz[SUP] 1 [/SUP], Philippe Barthélémy[SUP] 1 [/SUP], Justine Gantzer[SUP] 1 [/SUP]
Affiliations
- PMID: 34028132
- DOI: 10.1002/onco.13831
Abstract
We describe a large series of solid tumor patients in an early Coronavirus Disease 2019 (COVID-19) cluster of the eastern part of France. From February to May 2020, this multicenter retrospective study enrolled 212 cancer patients under treatment or on follow-up for any type of malignant solid tumor and positive for severe acute respiratory coronavirus 2. The mortality rate was 30%. Patients with gastrointestinal cancers were identified like a subset of more vulnerable cancer patients and immunotherapy or radiotherapy within 3 months from COVID-19 diagnosis were risk factors for death. The reported data support the essential need to be proactive and weigh the risks of morbidity from COVID-19 against the magnitude of benefits of intended cancer therapies during this pandemic. IMPLICATIONS FOR PRACTICE: This article supports the essential need to be proactive (treatment delay or modification) in oncology in the setting of pandemic. Indeed, we identified gastrointestinal cancers like a subset of more vulnerable cancer patients and found that immunotherapy and radiotherapy within 3 months from COVID-19 diagnosis as risk factors for death. The reported data indicate the necessity to weigh the risks of morbidity from COVID-19 against the magnitude of benefits of intended cancer therapies so that the situation would be different if there were another wave of COVID-19.
Keywords: COVID-19; Cancer; mortality; patients' management; retrospective cohort; risk factor.